Literature DB >> 18515815

The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.

G J S Jenkins1, J Cronin, A Alhamdani, N Rawat, F D'Souza, T Thomas, Z Eltahir, A P Griffiths, J N Baxter.   

Abstract

Deoxycholic acid (DCA) is a secondary bile acid implicated in various cancers of the gastrointestinal (GI) tract. In oesophageal adenocarcinoma, DCA is believed to contribute to carcinogenesis during reflux where stomach contents enter the lower oesophagus. It is imperative that we understand the mechanisms whereby oesophageal carcinogens function in order that therapeutic options may be developed. We have previously shown that DCA can damage chromosomes and does so through its generation of reactive oxygen species (ROS). We show here, after detailed experiments, that DCA appears to have a non-linear dose response for DNA damage. DCA induces DNA damage (as measured by the micronucleus assay) at doses of 100 microM and higher in oesophageal OE33 cells, but fails to induce such DNA damage below this cut-off dose. We also show that in terms of NF-kappaB activation (as measured by up-regulation of two NF-kappaB target genes) by DCA, a similar dose response is observed. This dose-response data may be important clinically as DCA exposure to the oesophagus may be used as a way to identify the 10% of Barrett's oesophagus patients currently progressing to cancer from the 90% of patients who do not progress. Only quantitative studies measuring DCA concentrations in refluxates correlated with histological progression will answer this question. We further show here that ROS are behind DCAs ability to activate NF-kappaB as antioxidants (epigallocatechin gallate, resveratrol and vitamin C) abrogate DCAs ability to up-regulate NF-kappaB-controlled genes. In conclusion, low doses of DCA appear to be less biologically significant in vitro. If this were to be confirmed in vivo, it might suggest that reflux patients with low DCA concentrations may be at a lower risk of cancer progression compared to patients with high levels of DCA in their refluxate. Either way, antioxidant supplementation may possibly help prevent the deleterious effects of DCA in the whole GI tract.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515815     DOI: 10.1093/mutage/gen029

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  36 in total

1.  Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells.

Authors:  Xiaofang Huo; Stefanie Juergens; Xi Zhang; Davood Rezaei; Chunhua Yu; Eric D Strauch; Jian-Ying Wang; Edaire Cheng; Frank Meyer; David H Wang; Qiuyang Zhang; Stuart J Spechler; Rhonda F Souza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-02       Impact factor: 4.052

Review 2.  Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katherine S Garman; Roy C Orlando; Xiaoxin Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

3.  New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.

Authors:  Brian J Reid; Rumen Kostadinov; Carlo C Maley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

4.  Diallyl Disulfide Suppresses the Inflammation and Apoptosis Resistance Induced by DCA Through ROS and the NF-κB Signaling Pathway in Human Barrett's Epithelial Cells.

Authors:  Cheng Feng; Yumei Luo; Yuanyuan Nian; Dong Liu; Xiaoran Yin; Jing Wu; Jia Di; Rong Zhang; Jun Zhang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 5.  Quality Management and Key Performance Indicators in Oncologic Esophageal Surgery.

Authors:  Ines Gockel; Constantin Johannes Ahlbrand; Michael Arras; Elke Maria Schreiber; Hauke Lang
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

6.  Adiponectin modulates DCA-induced inflammation via the ROS/NF-κ B signaling pathway in esophageal adenocarcinoma cells.

Authors:  Rong Zhang; Xiaoran Yin; Haitao Shi; Jie Wu; Pramod Shakya; Dong Liu; Jun Zhang
Journal:  Dig Dis Sci       Date:  2013-10-05       Impact factor: 3.199

Review 7.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

Review 8.  Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Authors:  Sebastian F Schoppmann; Ivan Kristo; Martin Riegler
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-05

Review 9.  Role of interleukin-6 in Barrett's esophagus pathogenesis.

Authors:  Katerina Dvorak; Bohuslav Dvorak
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

10.  Deoxycholate, an endogenous cytotoxin/genotoxin, induces the autophagic stress-survival pathway: implications for colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Hana Holubec; Katerina Dvorak; Carol Bernstein; Mary Pat Moyer; Harinder Garewal; Harris Bernstein
Journal:  J Toxicol       Date:  2009-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.